HEPATIC STELLATE CELL-DERIVED FSTL3 DEFINES AN ACTIVIN A-ACTRII AXIS AS A TARGET FOR REPURPOSING CLINICAL-STAGE ANTIBODIES IN ALCOHOL-RELATED LIVER DISEASE (AASLD 2026) - Oct 6, 2026 - Abstract #3028; Pres time: Nov 7, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; "We tested three late-stage clinical or FDA approved antibodies targeting different nodes of this pathway: garetsomab, sotatercept, and bimagrumab, all of which phenocopied FSTL3s protective effect in ALD. HSCderived FSTL3 protects against ALD by antagonizing a hepatocyte-autonomous Activin A–ActRII–p21 axis. Three distinct clinical-stage antibodies each recapitulate the protective effects of FSTL3, providing preclinical rationale to repurpose an existing pharmacologic pipeline as a novel therapeutic approach for a disease with no effective medical treatments."
Clinical • Hepatology • ACVR2A • TGFB1
|
|
Gloria Alvarez Sola1; Wei Zhang1; Jay Luther1; Esperance Schaefer2; Russell Goodman1
|